Sentence examples for dominant payer from inspiring English sources

The remaining vaccine examined, Zostavax, was initially licensed for adults (≥ 60 y) but was also included as the government is the dominant payer for Zostavax through the Medicare program.

Rivaroxaban may represent for payers a dominant option for the prevention of thromboembolic events in moderate to high risk AF patients in Greece.

From the perspective of the third-party payer, gargling is dominant due to the fact that the costs of gargling are borne by the participant.

If opposition politicians had long surmised that Mexico's ruling party was using its dominant position to channel tax-payer money illegally to its party operations, no evidence was ever assembled to prove those suspicions.

Unfortunately, "single-payer" remains stubbornly dominant in this debate, though Medicare for all has been bandied about by some advocates, including Bernie Sanders.

From the perspective of a third-party payer, both strategies are dominant versus non-vaccination, in terms of avoided diseases and deaths, ICER, and LYG.

From the perspective of the third-party payer, gargling is a dominant preventive strategy due to the fact that the opportunity cost of gargling is imposed on the participant.

It is highly likely these interventions do reduce costs to the payer as they continue to be dominant in the managed care environment.

23 The Belgian model, which drew on clinical data from a different trial 22 and used health state preference measures different from those in the present study, found that the aprepitant regimen was associated with a gain of 0.014 QALYs and was the dominant approach from the perspective of the Belgian health care payer.

There are three different types of health care systems based on who collects and provides health care: 1) A multi-payer system comprised of the government-run programs (the dominant insurer) and the private insurances: the government is neither the main healthcare provider nor the collector of money for health care.

From a Thai payer perspective, Thongprasert et al. [ 19] revealed that gefitinib is dominant compared to docetaxel in the second-line treatment without taking pharmacogenomic profiling into consideration.